Results 11 to 20 of about 237,025 (162)
CUT-OFF POINT OF PSA AND PSA DENSITY IN PROSTATE CANCER SUSPECTED PATIENTS
Jurnal Urologi Indonesia, 2016 Objective: In Hasan Sadikin General Hospital Bandung prostate biopsy is recommended for patients with prostate specific antigen (PSA) levels above 10 ng/mL or PSA density (PSAD) above 0.15 if PSA in between 4–10 ng/mL.
Daniel Simanjuntak, Ferry Safriadi
doaj +1 more source
Prostate International, 2013 Racial differences exist in the incidence of prostate cancer (PCa). Although many studies have looked at the performance of prostate-specific antigen (PSA) and PSA density (PSAD) in the detection of PCa, only a few have looked at it in relation to ...
Ahmad Anies Shahab +5 more
doaj +1 more source
Complexed Prostate-specific Antigen and the “Prostate-specific Antigen Gap” [PDF]
Clinical Chemistry, 1999 Jung et al. (1) reported an apparent gap between total serum prostate-specific antigen (t-PSA) and the sum of free PSA (f-PSA) plus α1-antichymotrypsin-PSA (ACT-PSA) in patients with prostate carcinoma (PCa) but not in those with benign prostatic hypertrophy (BPH).
Iain S Ross +5 more
openaire +1 more source
Tumor Biology, 1999 Approximately 40% of the prostate-specific antigen (PSA) purified from seminal fluid comprises cleaved or fragmented forms of PSA. These fragments are observed by reduced SDS-PAGE and have been identified in preparations of purified seminal plasma. The comparative analysis of 53 antibodies, submitted to an international PSA Workshop, with different PSA
T J, Wang +5 more
openaire +2 more sources
Glycotyping of prostate specific antigen [PDF]
Glycobiology, 2000 Measurement of serum levels of the prostate specific antigen (PSA) is now widely used for the diagnosis of prostate cancer and benign prostate hyperplasia. This serum marker is of value since it is derived only from the tissue of interest, but increased levels of PSA in serum do not allow a completely clear cut diagnosis of benign versus malignant ...
S, Prakash, P W, Robbins
openaire +2 more sources
Asian Journal of Andrology, 2015 In Western countries, clinical trials on prostate cancer screening demonstrated a limited benefit for patient survival. In the Asia-Pacific region, including Japan, the rate of prostate-specific antigen (PSA) testing remains very low compared with ...
Yasuhide Kitagawa, Mikio Namiki
doaj +1 more source
Clinical and Translational Radiation Oncology, 2022 Background and purpose: The treatment of biochemical recurrence (BCR) after prostatectomy is challenging as the site of the recurrence is often undetectable.
Adalsteinn Gunnlaugsson +10 more
doaj +1 more source
The effects of specific expression of apoptin under the control of PSES and PSA promoter on cell death and apoptosis of LNCaP cells [PDF]
Iranian Journal of Basic Medical Sciences, 2017 Objective(s): Apoptotic effect of apoptin has been demonstrated in numerous studies. However, its tumor specificity has been questioned by some reports.
Vida Mohammadi +6 more
doaj +1 more source
The diagnostic value of a new formula combining age and prostate volume in prostate cancer
Journal of Men's Health, 2022 Background and objective: This study combined two clinical indicators (age and prostate volume (PV)) to generate age to PV (AVR) ratio, whose diagnostic value for prostate cancer (PCa) was examined based on prostate specific antigen (PSA) in the range
Xiaobo Yang +8 more
doaj +1 more source
PROSTATE-SPECIFIC ANTIGEN VELOCITY AND REPEATED MEASURES OF PROSTATE-SPECIFIC ANTIGEN
Urologic Clinics of North America, 1997 Numerous studies evaluating different populations have shown similar findings with respect to repeated PSA measurements and PSAV. First, there is substantial within-individual variability between repeated PSA measures. Second, this variability between PSA measurements precludes the use of a simple change in PSA as a marker for prostate cancer.
H B, Carter, J D, Pearson
openaire +2 more sources